Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment
Public ClinicalTrials.gov record NCT00958269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment Including Subjects on Hemodialysis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and tolerability of dutogliptin in Type 2 diabetic subjects with moderate or severe renal impairment.
Study identification
- NCT ID
- NCT00958269
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 360 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2009
- Primary completion
- Aug 31, 2011
- Completion
- Oct 31, 2011
- Last update posted
- Feb 2, 2010
2009 – 2011
United States locations
- U.S. sites
- 23
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phenomix Investigational Site 115 | Tempe | Arizona | — | — |
| Phenomix Investigational Site 121 | Long Beach | California | — | — |
| Phenomix Investigational Site 110 | Lynwood | California | — | — |
| Phenomix Investigational Site 118 | Lynwood | California | — | — |
| Phenomix Investigational Site 119 | Orange | California | — | — |
| Phenomix Investigational Site 109 | Palm Springs | California | — | — |
| Phenomix Investigational Site 122 | Whittier | California | — | — |
| Phenomix Investigational Site 112 | Lauderdale Lakes | Florida | — | — |
| Phenomix Investigational Site 104 | Ocala | Florida | — | — |
| Phenomix Investigational Site 116 | Pembroke Pines | Florida | — | — |
| Phenomix Investigational Site 101 | Augusta | Georgia | — | — |
| Phenomix Investigational Site 117 | Honolulu | Hawaii | — | — |
| Phenomix Investigational Site 102 | Baton Rouge | Louisiana | — | — |
| Phenomix Investigational Site 100 | Rockville | Maryland | — | — |
| Phenomix Investigational Site 125 | Rockville | Maryland | — | — |
| Phenomix Investigational Site 114 | Springfield Gardens | New York | — | — |
| Phenomix Investigational Site 120 | Winston-Salem | North Carolina | — | — |
| Phenomix Investigational Site 107 | Columbia | South Carolina | — | — |
| Phenomix Investigational Site 111 | Nashville | Tennessee | — | — |
| Phenomix Investigational Site 103 | Fort Worth | Texas | — | — |
| Phenomix Investigational Site 106 | Houston | Texas | — | — |
| Phenomix Investigational Site 108 | San Antonio | Texas | — | — |
| Phenomix Investigational Site 113 | Alexandria | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
Recently updated Type 2 Diabetes Mellitus trials
Other public records listing Type 2 Diabetes Mellitus. Sorted by last update posted; newest first. Not a recommendation.
- NCT07743450: A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes Recruiting
- NCT07662044: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus Recruiting
- NCT07521475: Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes Recruiting
- NCT07662135: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin Recruiting
- NCT07662109: A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus Recruiting
- NCT07662213: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00958269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 2, 2010 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00958269 live on ClinicalTrials.gov.